![](https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg)
Friday, May 10, 2024
Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Impressive results. The company reported fiscal Q3 revenue of $376.4 million, beating our estimate of $341.8 million. Adj. EBITDA in the quarter was $46.6 million, also beating our estimate, which was $40.3 million. The robust 26% revenue growth was driven primarily by Pharmacy revenue, which grew 80% over the prior year period.
Strong OEP. Revenue from the Senior segment was 20% better than our estimate, indicating a favorable Medicare Advantage Open Enrollment Period for the company. Notably, Senior segment adj. EBITDA margins were 30% in the quarter.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.